Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma.;
Hyderabad: Drugmaker, NATCO Pharma Limited, today announced the launch of first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market.
The product was launched by NATCO's commercial partner Juno Pharmaceuticals Pty Ltd.
Pomalidomide is prescribed for the treatment of Multiple Myeloma and Kaposi Sarcoma.
Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in many bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts. Myeloma can also damage the bones and the kidneys and weaken the immune system.
Read also: NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market
Pomalyst registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.
Pomalyst is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners.
Read also: Natco Pharma launches Chlorantraniliprole (CTPR) pesticide formulated combination products in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.